Regulations for Registration of Medicinal Products Article 4

The terms used in this chapter are defined as follows:1.New drugs: the new drugs described in Article 7 of the Pharmaceutical Affairs Act.2.Generic drugs: pharmaceutical preparations identical to a drug already approved in Taiwan in the aspects of ingredients, dosage form, contents and efficacy.3.Bio-pharmaceuticals: serum, antitoxin, vaccines, toxic, bacteria sap and products manufactured based on the theories of microbiology and immunology.4.Substances (Active pharmaceutical ingredients): An active substance or ingredient manufactured through physical and chemical processes or bio-tech procedures and with pharmacological effects that are often used for the manufacturing of drugs, bio-pharmaceuticals or bio-tech products.5.Radiopharmaceutical drugs: drugs meeting the definition given in Article 6, containing radioactive substances for human uses. After being administrated to humans, the drug can diagnose, monitor, treat, alleviate disease conditions or achieve other medical effects.
中文原文 藥品查驗登記審查準則第4條
本章用詞定義如下:
一、新藥:指本法第七條所稱之新藥。
二、學名藥:指與國內已核准之藥品具同成分、同劑型、同劑量、同療效之製劑。
三、生物藥品:指依據微生物學、免疫學學理製造之血清、抗毒素、疫苗、類毒素及菌液等。
四、原料藥(藥品有效成分):指一種經物理、化學處理或生物技術過程製造所得具藥理作用之活性物或成分,常用於藥品、生物藥品或生物技術產品之製造。
五、核醫放射性藥品:指符合本法第六條所稱藥品之定義,並係以具有放射活度之物質使用於人體內,經體內分佈之後,可被用來診斷、監測、治療、緩解疾病或具其他醫療效能之藥品。

English translation for reference only; the Chinese text prevails. Not legal advice.